METABOLIC DISORDERS

P239
NOVEL PEX3 MUTATIONS IDENTIFIED AS THE CAUSE OF A PEROXISOMAL BIOGENESIS DISORDER WITH MODERATE CLINICAL PHENOTYPE
Clarisa Maxit1, Ines Denzler1, Delfina Marchione1, Guillermo Agosta1, J Koster2, Ronald2, Wänders3, S Ferrandina4, Hans Waterham5, Hospital Italiano de Buenos Aires, Argentina; 2Academic Medical Centre, Amsterdam, The Netherlands.

Background: Peroxisome biogenesis disorders (PBDs) may have variable clinical expression, from severe, lethal to mild phenotypes with progressive evolution. PBDs are caused by mutations in PEX genes, which encode proteins, called peroxins, involved in the assembly of the peroxisome.

Objectives: To report a patient heterozygous for two novel mutations in the PEX3 gene with less severe phenotypic expression than reported previously for PEX3 patients.

Case Report: A five years old boy, first child of unrelated parents, presented with psychomotor retardation, axial and peripheral muscular hypotonia and nephrocalsinosis at 3 months of life. He was born at term, and perinatal history was uneventful. At 18 months old he presented progressive spastic paraparesis, neurogenic bladder and nystagmus that evolved to bilateral cataract at 4 years old.

Methods: Peroxisomal parameters were studied in cultured skin fibroblasts. PEX genes were sequenced in DNA isolated from fibroblasts.

Results: Catalase immunofluorescence showed a peroxisomal mosaic pattern with all cells containing peroxisomal membrane structures. Immunoblotanalysis for acyl CoA oxidase and peroxisomal thiolase was normal. Sequencing identified two heterozygous, pathogenic mutations in the PEX3 gene.

Conclusion: Our patient expands the clinical spectrum for PEX3 patients, because PEX3 mutations usually result in a severe, early lethal phenotype.

P240
MANAGEMENT OF PATIENTS WITH ADRENOLEUKODYSTROPHY

Introduction: X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal inborn error of metabolism. Currently, the only effective treatment in the cerebral phenotype is allogeneic hematopoietic stem cell transplantation (HSCT) in selected cases meeting the outcome criteria by Peters C et al. The aim of this study was to present a working model for the assessment of X-ALD patients in a multidisciplinary team consisting of neurologists and specialists in inborn errors of metabolism.

Material and methods: Of 25 patients seen, 16 were symptomatic and nine asymptomatic with elevated plasma very long chain fatty acids. Neurofunctional (Raymond scale), neuroradiological (Loes score), and cognitive (WISC IV) criteria were assessed. Criteria for HSCT were according to Peter C et al.

Results: Of the 15 symptomatic patients, 11 HSCT was not indicated because of advanced disease. All patients received symptomatic treatment (hormone-replacement therapy). Four were candidates for HSCT. Two received HSCT (one died 9 months after transplantation) and two possible donors are looked for. Of the presymptomatic patients (10), five received preventive dietary treatment (Lorenzo’s oil and diet). One patient with endocrinological manifestations (pure Addison’s) is also under control.

Conclusion: We consider that X-ADL patients should be evaluated by a multidisciplinary team from disease onset to provide adequate management and follow-up of the disease and its comorbidities as well as family counseling. Lamentablemente la mayoría de los casos índices no cumplen criterios para HSCT.

P241
BIOTERPIN DISORDER CAUSING HIPERPHENYLALANINEMIA: TWO DIFFERENT CASES
Cristina Naquiera Marques Alencar, Avessandra Costa Cardoso Oliveira, Juliana de Castro Naves Peixoto, Paulo Roberto Alves Seixas, Janaina Monteiro Chaves, Renata Brasil Reis Pereira, Cristiane Sales Low, Maria Vale Cavalcante, Maria Angélica Cavalcante Barbosa Viana, Christian Muller, Juliana Oliveira Ferreira, Hospital de Base do Distrito Federal & Hospital da Criança de Brasília, Brazil

Hyperphenylalaninemia (HPA) may rarely be caused by defects in the synthesis or recycling of tetrahydrobioterpin (BH4), an essential co-factor in the phenylalanine hydroxylase activity (PAH) reaction. Approximately 2% of patients with HPA have a defect in one of the four enzymes responsible for maintaining BH4 levels. Guanosine triphosphate cyclohydrolase (GTPC) and pyruvate tetrahydrobioterpin synthase (PTPS) are essential enzymes for biosynthesis, whereas pterin-4a-carbolamine dehydratase (IPCD) and dihydropteridin reductase (DHPR) are responsible for recycling. The case report is about two different children with two years old, one of them with defect in GTPCH and other in DHPR. P.S.F. presented hypotonia with 3 months and constated a delayed neuropsychomotor developmental (DNMD) in the first year of life. Neurologic exam certified pyramidal signs and trunk hypotonia. During the diagnostic investigation, was observed HPA with abnormal values, but no high, which seems not compatible with phenilketonuria (PKU). The possibility was a secondary secondary HPA, with a different enzyme defect. Complementary exam established very low levels of neopterin and bioterpin that indicates GTPCH defect. Other child, J.P.F., began clinical manifestations with epilepsy around 2 months and DNMD. The parents are consanguines. Neurologic exam demonstrated irritability and hypotonia. The inborn metabolism errors screen showed elevated serum phenylalanine and normal tyrosine. Adicional laboratory investigation confirmed DHPR absent activity. Bioterin disorders result in deficiencies of the neurotransmitters L-dopa and 5-hydroxytryptophan. Should be highlighted the early treatment could be modify the prognostic and register a rare cases of HPA without PKU.

P242
TAY-SACHS DISEASE B1 VARIANT: CASE REPORT
Cristina Naquiera Marques Alencar, Juliana Oliveira Ferreira, Avessandra Costa Cardoso Oliveira, Juliana de Castro Naves Peixoto, Paulo Roberto Alves Seixas, Janaina Monteiro Chaves, Renata Brasil Reis Pereira, Cristiane Sales Low, Maria Vale Cavalcante, Maria Angélica Cavalcante Barbosa Viana, Christian Muller, Hospital de Base do Distrito Federal & Hospital da Criança de Brasília, Brazil

Tay-sachs disease (TSD) is a lysosomal storage disorder which has autosomal recessive inheritance and low incidence. Occurs due to hexosaminidase A (HEA-X) enzyme deficiency in a subunit. The B1 variant is resulted from an altered substrate specificity of HEA-X, wherein the mutated enzyme retains the ability to degrade the artificial substrate but not the sulfated or natural substrate in vivo. The highest incidence, 3, 1 per 100.000 live births, for B1 variant of GM2 gangliosidoses has been described in Portugal, which has been suggested as the point of origin of a founder mutation seen in Brazilian patients. The case report is about a three year old male child, who presented one year earlier with regression on gait, speech and coordination. Then, he develops swallow disturbance and spasticity. The child was admitted to clinical investigation and diagnostic procedures. MRI and cerebral spinal fluid were normal. The inborn metabolism errors screen for HEA-X activity was normal, but when this exam was performed in another substrate (sulfate) it was deficient, that is called HEA-X MUGS activity. This variant B1 diagnose of TSD is rare variant disease and can be performed with this test. The genetic counselling was explained to parents giving the information about 25% of chance to descendant recurrence. The importance of this case is the challenge to make a differential diagnosis of acute ataxia in childhood and pay attention to progressive symptoms presence, which other pathologies must be suspected, like metabolic diseases.
**P243**

"MUCOPOLYSACCHARIDOSIS TYPE IV A: EVIDENCE OF PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT"

Felipe Borlot¹, Paula R Arantes², Caio R Quaio³, José F S Franco¹, Charles M Lourenço⁴, Israel Gomy⁵, Debra R Bertola⁶, Chong Ae Kim⁷. ¹Genetics Unit, Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (USP), Brazil; ²LIM 44 - Departamento de Radiologia da Faculdade de Medicina da USP, Brazil; ³Hospital das Clínicas de Ribeirão Preto, Faculdade de Medicina de Ribeirão Preto, USP, Brazil.

**Introduction:** Mucopolysaccharidosis type IV A is a rare lysosomal storage disease caused by a deficiency of N-acetylgalactosamine-6-sulfatase. Studies usually focus on skeletal abnormalities and their consequences. This study explores the neurological manifestations in a cohort of mucopolysaccharidosis type IV A patients, with a detailed focus on brain and spinal MRI findings.

**Methods:** We performed a cross-sectional study involving nine patients with a biochemical confirmation of mucopolysaccharidosis type IV A. The protocol consists of a comprehensive clinical examination and brain/spinal cord MRI analysis for all subjects.

**Results:** The mean age was 16.4 years (± 5.7) and the mean onset of symptoms was 11.5 months (± 6.3). Overall, cognition was spared and brain/spinal cord MRI analysis for all subjects.

**Conclusion:** Our experience with mucopolysaccharidosis type IV A patients supports the evidence of CNS involvement. We emphasize the importance of regular clinical assessment by the complete MRI studies, as an attempt to detect the early signs of spinal cord compression. This evaluation may be especially important before surgical interventions, as occult lesions may become symptomatic and promote postoperative unfavourable outcomes.


**P244**

"REMOTE SPINAL CORD INJURY IN MUCOPOLYSACCHARIDOSIS TYPE IV A AFTER CERVICAL DECOMPRESSION"

Felipe Borlot¹, Paula R Arantes², Alberto Capel Cardoso³, Chong Ae Kim⁴. ¹Genetics Unit, Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (USP), Brazil; ²LIM 44 - Departamento de Radiologia da Faculdade de Medicina da USP, Brazil; ³Hospital de Neurocirurgia, Hospital das Clínicas da Faculdade de Medicina da USP, Brazil.

**Introduction:** Mucopolysaccharidosis type IV A (MPS IV A, Morquio A syndrome, MIM #253000) is an autosomal recessive lysosomal storage disorder, characterized by inability to break down keratin-sulfate and chondroitin-6-sulfate. Skeletal changes may result in disabling neurological complications. Atlantoaxial instability and cervical spinal cord compression are common; posterior occipitocervical fusion with (or without) spinal decompression is recommended.

**Method:** Case description. This report describes a patient who required occipitocervical fusion and suffered an irreversible thoracic paraplegia in the immediate postoperative period.

**Case description:** A 17-year-old boy diagnosed with MPS IV A at the age of 5 had slowly developed progressive signs of spinal cord compression. Prior to surgery, his neurological examination showed MRC grade 3 in the upper limbs and 2 in the lower limbs, hyperactive deep tendon reflexes without clonus or Babinski sign, and no sensory impairment. His spinal MRI showed atlantoaxial subluxation and signs of myelomalacia at C1-C2 levels. Postoperatively, after occipitocervical fixation in the prone position, he developed acute paraplegia, sensory losses below T3 and striking MRI abnormalities far from the maximum compression site.

**Discussion:** MPS patients may develop remote spinal cord injuries from maximum compression sites after general anaesthesia in the prone position due to impaired cardiac output. The role of intraoperative monitoring with motor and/or somatosensory evoked potentials remains controversial in literature, although evoked potentials may indicate early signs of spinal infarct; they cannot prevent this unexpected complication. This outcome is unusual, but healthcare professionals, patients and their parents should be aware to this devastating complication after spinal cord decompression. Neurology April 15, 2014 vol62 no. 15 1382-1383. Copyright © 2014, AAN Enterprises, Inc.

**P245**

"NEW INSIGHTS IN MUCOPOLYSACCHARIDOSIS TYPE VI: NEUROLOGICAL PERSPECTIVE"

Felipe Borlot¹, Paula Ricci Arantes², Caio Robledo Quaio³, José Francisco da Silva Franco¹, Charles Marques Lourenço⁴, Debora Romeo Bertola⁵, Chong Ae Kim⁶. ¹Genetics Unit, Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (USP), Brazil; ²LIM 44 - Departamento de Radiologia da Faculdade de Medicina da USP, Brazil; ³Hospital das Clínicas de Ribeirão Preto, Faculdade de Medicina de Ribeirão Preto, USP, Brazil.

**Objective:** Mucopolysaccharidosis type VI is a rare autosomal recessive storage disorder, caused by a deficiency of arylsulfatase B. Data on neurological involvement in mucopolysaccharidosis type VI patients under enzyme-replacement therapy are limited. This study explores the neurological and magnetic resonance imaging findings in a sample of mucopolysaccharidosis type VI patients receiving enzyme-replacement therapy.

**Methods:** We performed a cross-sectional study including six patients with biochemical confirmation of mucopolysaccharidosis type VI. All patients had at least two consecutive years receiving intravenous enzyme-replacement therapy. The protocol included a comprehensive clinical examination, brain and spinal cord magnetic resonance imaging for all subjects.

**Results:** Overall, cognition was spared, while we found presence of hearing impairment, increasing in deep tendon reflexes, and deep sensation reduction in three patients. In addition to the classical mucopolysaccharidosis abnormalities, brain imaging studies demonstrated: (i) morphological changes in anatomy of middle cranial fossa; (ii) sella shape abnormalities; (iii) diploic thickness over venous sinus; (iv) dolicocephaly; (v) and sinus pericranii. Even in asymptomatic or mild compromised patients, spinal cord compression was found. In four patients we noticed atlantoaxial joint subluxation and three had cervical spinal stenosis. Degenerative processes involving vertebral column, including vertebral bodies’ indentations, disc-oosteophytes complexes, and Schmorl’s nodes were present in all patients.

**Conclusions:** Neuroaxis involvement was a constant finding in our small sample; unfortunately, neurological examination might not predict the severity of the disease in course. Moreover, imaging studies should not be performed according exclusively clinical parameters, once we have demonstrated that neurological involvement may be silent in mucopolysaccharidosis type VI.

Brain Dev. 2013 Aug 21 2013 S0387-7604(13)3237-4. Copyright © 2013, Published by Elsevier B.V.
hypoignal at globus pallidus, and FLAIR hyperignal at postero-lateral putamina. Reduced putaminal volume and cerebral vertebral alterations were also noted.

**Conclusions:** This large case series for such a rare disorder showed pyramidal and extrapyramidal signs in most patients, which were previously well known in this condition. In addition, we detected cognitive or behavioral impairment in half of the patients, and also mild oculomotor abnormalities not previously reported in this condition. MRI confirmed abnormalities in basal ganglia in all subjects submitted to this exam.

**P247**

**DIFFERENTIAL DIAGNOSIS OF THE CHRONIC ENCEPHALOPATHIES: THE IMPORTANCE OF FOLLOWING THE PSYCHOMOTOR DEVELOPMENT MARKS**

Tania Saad,1 Denise Santana,2 Ana Paula Rodrigues Lazzari Arnáu,2 Lúcio José Santa-Ignêz,2 Dafne Horowitz,1 Carmelo Conti,1 Fernanda Veiga Góes,1 Flávia Nardes,1 Ana Carolina Espósito,3 Sheila Lucena1 Brazilian Academy of Neurology Brazilian Society of Pediatric Brazilian Society of Child Neurology, Brazil;1 Fernandes Figueira Institute (IFF), Brazil

**Objectives:** Emphasize the need to search, in different evolutive moments, the etiology of psychomotor development deviations to distinguish the chronic non-progressive encephalopathies from the progressive ones through the description of a late diagnosis of a Niemann-Pick type C disease (NPC) with a previous diagnosis of chronic non-progressive encephalopathy.

**Case report:** PPP, male, 3 years old, first presented with motor development delay, followed by a delay in language acquisition. A MRI in 2011 suggested CMV lesion and two USG in the same year appeared normal. Follow up showed progressive motor losses and worsening of cognition. New investigation in 2012, revealed vertical supranuclear gaze palsy, ataxia, eventual dysphagia and splenomegaly. Bone marrow aspiration showed crinkled-paper, cytoplasm cells, questioning Gaucher disease. As the enzymatic test was negative and the patient evolved with gelastic cataplexy, it was initiated the research to NPC, with a Niemann-Pick suspicion index (NP-SI) of 142 points. The hypothesis was confirmed by a positive Filipin test. In June/2013 Miglustat was initiated as substrate reduction therapy, and imipramine to cataplexy.

**Conclusion:** NPC is rare and polymorphic making it difficult to diagnose, specially when the visceral signs present themselves later. The use of the Niemann-Pick suspicion index oriented the investigation and helped in the case elucidation. This case makes clear that systematization is essential for the differential diagnosis of the psychomotor development delays.

**Discussion / conclusion:** The tetrahydrobiopterin metabolism disorders are rare forms of hyperphenylalaninaemia, representing 2% and make differential diagnosis with phenylketonuria, but more severe, worse therapeutic response and substantially different treatment. The suspected diagnosis by neonatal screening with subsequent early confirmation by specific laboratory tests are extremely important because they allow proper treatment and prevention of progressive neurological damage.

**P248**

**TETRAHYDROBIOPTERIN (BH4) DEFICIENCY: A CASE REPORT**

Pricila Souza Soares,1 Leticia Leal Miranda, Fernanda de Castro Monti, Mauricio Rangel Zamboni, Camila Almeida Santos, Ana Carolina de Mello Cyrino, Patricia Guhiken Takahashi, Juliana Barbosa de Pádua Pinheiro, Pollyanna Barbosa Lima Cerqueira, Clarissa Bueno, Fernando Kok, José Albino da Paz, Letícia Pereira Brito Sampaio, Erasmo Barbante Casella, Maria Joaquina Marques-Dias, Humberta Contri Reed. Hospital das Clínicas da Universidade de São Paulo - HCFMUSP, Brazil

**Introduction:** Tetrahydrobiopterin (BH4) is an essential cofactor for phenylalanine, tyrosine and tryptophan hydroxylase and its deficiency results in hyperphenylalaninaemia and depression of neurotransmitters in the central nervous system. It is caused by defects in one of four enzymes responsible for its synthesis or regeneration. Typically manifests in the neonatal period or after the first year of life with motor delayed and / or cognitive impairment, hypotonia, movement disorders, seizures or autonomic symptoms.

**Objective:** To describe a case of tetrahydrobiopterin deficiency following in the Clinic of Metabolic Diseases, Hospital das Clínicas USP.

**Case Description:** Male, 3 years old, son of non-consanguineous parents, with no relevant gestational history, when he was asymptomatic with 7 days of life received neonatal screening for phenylketonuria changed. Initiated dietary restriction without a satisfactory answer. Evolved with hypotonia, developmental delay, gait ataxia and choreiform movements in hands. Introduced sapropterin with symptom improvement, currently presenting language delay. Biopterin and neopterin undetectable in urine and normal dihydropterin reductase activity. Tomography and magnetic resonance of brain unchanged.

**Discussion / conclusion:** The tetrahydrobiopterin metabolism disorders are rare forms of hyperphenylalaninaemia, representing 2% and make differential diagnosis with phenylketonuria, but more severe, worse therapeutic response and substantially different treatment. The suspected diagnosis by neonatal screening with subsequent early confirmation by specific laboratory tests are extremely important because they allow proper treatment and prevention of progressive neurological damage.

**P249**

**INSIGHTS INTO THERAPEUTIC MECHANISM OF L-ARGININE THERAPY ON CEREBROVASCULAR ACTIVITY AND CEREBRAL BLOOD FLOW IN MELAS SYNDROME**

Lance H Rodan1, Julian Poublanc1, Olivia Pucci1, Joseph A Fisher2, Tien Wong1, Eugen Hläniy1, David Mkuki1, Ingrid Ten1 Division of Neurology, Dept. of Pediatrics, Hospital for Sick Children, University of Toronto; ‘Dept. of Medical Imaging, The Toronto Western Hospital, University of Toronto

**Background:** MELAS syndrome is characterized by recurrent stroke-like episodes that constitute a major source of morbidity and mortality. The latter are presumed to result from both direct neuronal energy failure and functional angiopathy. It has been suggested that L-arginine reduces frequency and severity of stroke-like episodes, but the underlying mechanism is unclear.

**Methods:** We performed a case control study in 3 siblings with MELAS syndrome to evaluate baseline cerebral blood flow (CBF) and perfusion using BOLD-fMRI. We then conducted a prospective clinical trial pilot study to assess the response of these parameters to single dose and 6-week steady-state oral L-arginine.

**Results:** MELAS subjects had lower serum arginine levels, and demonstrated decreased CBF and increased cerebral perfusion at baseline relative to controls. The latter abnormalities correlated with percentage of mutant mtDNA in blood. On regional analysis, mean CBF was reduced to a greater degree in frontal compared to occipital cortex. Following L-arginine therapy, MELAS subjects showed an increase in CBF in frontal cortex and a corresponding decrease in occipital cortex; CBF globally was unchanged. There was a dramatic reduction in hyperperfusion following steady state L-arginine in one MELAS subject.

**Discussion:** Intercital vascular reactivity and cerebral perfusion are abnormal in MELAS syndrome in accordance with disease severity. L-arginine therapy does not improve overall CBF interictally; however, it seems to selectively improve CBF in the regions that are most impaired at the expense of less abnormal regions. It may also decrease hyperperfusion, possibly by improving energy metabolism or normalizing vascular tone.

**P250**

**RAPID CLINICAL AND NEURORADIOLOGICAL REVERSAL OF STROKE-LIKE EPISODES IN MELAS SYNDROME FOLLOWING HIGH DOSE L-ARGININE**

Ishita Siddiqui1, Elysa Widjaja2, Ingrid Ten1.1, University of Toronto, 2Division of Neurology, Dept. of Pediatrics, The Hospital for Sick Children, Toronto, Ont., Canada

**Introduction:** Pathophysiology of stroke-like episodes (SLEs) in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes) is presumed to involve mitochondrial energy failure causing neuronal injury and microangiopathy. L-arginine (L-Arg) during acute SLEs may be associated with a reduction in severity of SLEs.

**Case description:** A 10-year-old boy with mtDNA A3243G tRNA-Leu mutation presented with acute encephalopathy, right focal seizures, motor apraxia and expressive aphasia. MRI showed left temporal lobe gyrfiform cortical diffusion restriction with mass effect. He was treated with oral L-Arg 500 mg/kg/d and within 24 hours showed rapid improvement of symptoms. He suffered repeated emesis of his L-Arg with recrudescence encephalopathy, apraxia and aphasia. He was started on iv L-Arg 500mg/kg/d for 4 hours and then 200mg/kg/d for 48 hours and symptoms quickly reversed again to baseline. L-Arg was then slowly tapered to 1 g tid po maintenance. At 13 years, he presented with an URTI and emesis. Six days later he suffered acute intermittent frontal headaches with transient diplopia and vomiting. MRI showed new symmetric lesions of the putamen and lesion of the rightpons. He was again treated with high dose iv L-Arg. Within 24 hours he had complete resolution of symptoms. MRI repeated 3 days later showed resolution of the pontine lesion.
Discussion: L-Arg is converted to nitric oxide, which is important in vasodilation and is a precursor for creatine and may improve TCA cycle anaplerosis. The consistent reversal of SLEs following high dose L-Arg in this case supports a therapeutic response.

**P254**

**QUANTITATIVE MEASUREMENT OF CEREBRAL OXYGEN EXTRACTION FRACTION USING MRI IN PATIENTS WITH MELAS IN DIFFERENT PHASES**

Jiang Xi Xiao, Lei Yu, Sheng Xie, Xiaodong Zhang. 1 Department of Radiology, Peking University First Hospital, Beijing, China; 2 Department of Radiology, China-Japan Friendship Hospital, Beijing, China; 3 Department of Neurology, Peking University First Hospital, Beijing, China

Aim: We aimed to quantify the cerebral OEF using MRI in patients with MELAS in different phases.

**METHOD AND MATERIALS:** From December 2009 to December 2013, 42 patients with MELAS were examined by MR, nineteen patients in different phases. Twenty-six healthy volunteers were recruited for control subjects.

A newly-designed sequence, named gradient-echo sampling of spin echo (GESSE), was applied to obtain the cerebral OEF data on the axial section just above the lateral cerebral ventricle. Six regions of interest (ROI) were placed on the section. We obtained six OEF values and then calculated the mean value, which was the cerebral OEF of this section.

In the 17 patients with unilateral cerebral involvement in acute and subacute phase, additional ROIs were placed on the lesions and the uninvolved contralateral counterparts.

**RESULTS:** Significant difference in cerebral OEF was found among different groups. OEF was reduced in the patients with MELAS compared with normal people, and the OEF values in the acute and subacute lesions were lower than those in the interictal phase. (acute and subacute phase: 0.271±0.007; the interictal phase: 0.293±0.002; volunteers: 0.319±0.006, X² = 25.4, P<0.001). Fifteen of 17 selected ROIs have lower values than the uninvolved contralateral hemispheres (Z =–2.20, P = 0.028).

**CONCLUSION:** Our study showed decreased utilization of oxygen in the brains of MELAS patients during different phases of this disease. The quantification of cerebral OEF, might be applied to evaluate the pathogenesis and prognosis of MELAS.

**P255**

**ROLE OF PLASMA AMINO ACIDS AND URINARY ORGANIC ACIDS IN DIAGNOSIS OF MITOCHONDRIAL DISEASES IN CHILDREN**

Hamed M Shatla, Hoda Y Tomoum, Solaf M Elayed, Iman A Elagouza, Rania H Shatla, Moustafa M Mohnen, Ashraf N Hamed. Department of Pediatrics, Ain Shams University, Cairo, Egypt

Dissocia diagnostic in mitochondrial diseases (MD) results not only from the wide spectrum of symptoms and signs but also from the absence of a reliable screening or diagnostic biomarker.

**Aim:** To investigate the likelihood of MD in patients with symptoms and signs suggestive of MD through quantitative measurement of plasma amino acids, and urinary organic acids.

**Methods:** Twenty patients with symptoms and signs suggestive of MD, were further evaluated by quantitative plasma aminoacids and urinary organic acids assay and neuroimaging.

**Results:** Plasma amino acidic results revealed elevation of alanine in 11 patients, of Glycine in five and proline in two patients. Abnormal urinary organic acid analysis was present in six patients; increased urinary lactate (20%), dicarboxylicaciduria (15%) and urinary ketone bodies (10%). According to MD scoring system (Wolf and Smeitink, 2002), upon enrollment our patients scored as possible MD. At end of study, five patients still scored as possible MD, eight patients were considered probable MD and seven patients as definite MD. All patients with definite MD had elevated serum lactate. Elevated urinay lactate in three patients was the only urinary organic acids abnormality in them. Plasma amino acid showed elevated alanine in all patients with definite MD, whereas proline was elevated in one. MRI brain showed atrophic changes in one patient and bilateral basal ganglia hyperintensity in another.

**Conclusion:** Urinary organic acids and quantitative plasma amino acids essay is a useful part of the work up for MD, especially when the economic burden and absence of specialized centers limits the diagnostic ability.

**P256**

**CLINICAL, BIOCHEMICAL AND GENETIC SPECTRUM OF MITOCHONDRIAL DISORDERS IN EGYPTIAN CHILDREN: A STUDY OF 15 CASES**

Laila Abdel Moteleb Selim1, Dina Ahmed Mehany2, Rudy Vancoster3, Sawsan Abdel Hadi Hassan2, Iman Gamal el Din Mahmoud4, Doaa Abdol2, Mariane Youssry Grgi1, Joel Smet2. 1 Cairo university Children hospital, Egypt; 2 Clinical and Chemical Pathology Department, Cairo University, Egypt; 3 Ghent University Belgium, Belgium; 4 Pediatric Neurology and Metabolic Department, Ghent University, Belgium

**Introduction:** Mitochondrial encephalomyopathies are a growing group of diseases with a large variety of clinical presentations ranging from a well defined clinical syndromes to non specific manifestations as failure to thrive, hypotonia, seizures, global developmental delay, cardiomyopathy, visual or hearing loss. The objective of this study is to describe the clinical, biochemical and genetic spectrum of 15 Egyptian patients with confirmed mitochondrial respiratory chain disorder.

**Subjects and Methods:** This is a retrospective study which included 62 patients with and age ranging from 9 months-25 years referred to the neurometabolic Unit at Cairo University children Hospital for evaluation for a possible mitochondrial respiratory chain disorder. They were 35 males/27 females. All patients were subjected to thorough neurological examination, basic lab investigations, expanded metabolic panel, and molecular diagnosis for mitochondrial syndrome.

**Results:** 15/62 patients has been confirmed with respiratory chain disorders. Three patients were diagnosed as MNGIE, one patient with MELAS, one patient with mitochondrial depletion syndrome, one patient with mitochondrial myopathy, 5 patients with complex I deficiency (1/5 presenting as biotin responsive striatal necrosis), 2 patients with combined complex I & IV deficiency, 2 patients with LHON.

**Conclusion:** Mitochondrial disorders have a wide spectrum of clinical presentations accounting for the marked delay in the diagnosis. High degree of suspicion is necessary to start a comprehensive work up combining clinical, biochemical, pathological and molecular data to confirm the diagnosis.

**P257**

**FIRST CASE OF GLUT1 DEFICIENCY SYNDROME IN A 2-YEAR-OLD ESTONIAN GIRL: A CASE PRESENTATION**

Stella Pöldsepp, Kati Toom, Katrin Dunapi, Üh Väher, Tiina Talvik, Inga Talvik. 1 Children’s Clinic, Tartu University Hospital, Estonia; 2 Neurology Clinic, Tartu University Hospital, Estonia; 3 Department of Pediatrics, University of Tartu, Department of Genetics, United Laboratories, Tartu University Hospital, Estonia

**Introduction:** Glucose transporter-1 (GLUT1) deficiency syndrome is caused by heterozygous mutations in the SLC2A1 gene, resulting in impaired glucose transport into the brain and hypoglycorrhachia. The clinical spectrum is wide, but it is classically characterized by treatment-resistant epilepsy, developmental delay and complex movement disorders.

**Case Description:** The patient was born at term from normal pregnancy and delivery. She was consulted repeatedly by child neurologist due to delayed psychomotor development, central hypotonia, ataxia and seizures. Seizures started at the age of 10 months and at 1y 4 months she had had 3 generalized tonic-clonic seizures and 3 eye-rolling episodes. All interictal electroencephalograms were normal and she was treated with levetiracetam. Magnetic resonance imaging, at 10 months and 1y 5 months, showed changes in white matter signal, indicating to delayed myelination. Full metabolic workup was negative, except elevated plasma alanine, suggestive of possible mitochondrial disorder. At 1y 5 months muscle biopsy was performed and mitochondrial disorders were excluded. At the age of 2y 1months cerebrospinal fluid (CSF) analysis showed low CSF glucose (2.0 mmol/l), normal range 3.3-4.4 mmol/l) and decreased CSF-to-blood glucose ratio (0.358) in the absence of hypoglycemia. Sequence analysis of SLC2A1 revealed a heterozygous mutation (c.968_972del p.V323fs*56) and GLUT1 deficiency syndrome was diagnosed at the age of 2y 1months.
Treatment with ketogenic diet was started immediately with favourable response.

**Conclusion:** This is the first case of GLUT1 deficiency syndrome in Estonia. Recognizing GLUT1 deficiency syndrome is important, since it is effectively treated by ketogenic diet.

The study was supported by the EuroEPINOMICS grant SARLA 11091E.

---

**P255**

**CHONDRODYSPLASIA PUNCTATA OR CONRADI-HÜNNERMAN SYNDROME: THE FIRST GUATEMALAN CASE**

Christian D. López, 1 2 3, Elie De Leon, 4 Hugo H Galvez, 1 2 3.

1 2 3 Asociación de Epilepsia de Guatemala; 1Universidad de San Carlos de Guatemala; 2Pediatric Department, Hospital Nacional de Occidente, Quetzaltenango, Guatemala; 3Hospital Nacional de Occidente, Guatemala

AIM: Conradi-Hünnemann syndrome (CHS) is clinical and genetically heterogenous disorder characterized by punctiform calcification of the bones (1). The clinical features describe includes skin defect linear or whorled atrophic and pigmenary lesions, coarse lustreless hair, alopecia, cataracts, and skeletal abnormalities. We present a patient with this clinical feature, like the first Guatemalan case reported of CHS.

**PATIENT:** We present a girl of 18 months of age, product of third pregnancy, no prenatal or delivery problems, mother denied intake warfarin or any drugs during pregnancy, also denied consanguinity. Came to consult for development delay and short stature. The first consult occurrence age 2 months, we found skin lesions: erythematous skin lesions, alopecia, ichthyosis form, atrophoderma, and coarse lustreless hair, skeletal defects: macrocephaly with frontal prominence, rizomelic shortening of the limbs, scoliosis. Also we found hypertonic posture, without weakness, osteotendinous reflex was normal, good visual contact language delay. The MRI made at 11 months shows brain atrophy with frontal pachygyria. The X ray show punctiform calcifications and injuries punch of the long bones, in femoral, humerus, tibia, and iliac bones. Several infections in the first year of life.

**DISCUSSION:** CHS it’s a paroxysmal disorder who interfere with the normal formation of cholesterol. We present a first Guatemalan case, a girl with many clinical features described before in CHS, but also with characteristic not described yet, like macrocephaly with brain atrophy, and frontal Pachygyria. We believe that it’s part an spectrum of Peroxisomal Disorders.

---

**P256**

**LYSINURIC PROTEINURIA: FIRST GENETICALLY PROVEN CASE FROM INDIA**

Vivek Jain1, Rajeev Bansal2, Sunita Bajisma2. 1Santokh Durlabhji Hospital, Jaipur, Rajasthan India; 2Center of Medical Genetics, Sir Ganga Ram Hospital, New Delhi

Lysinuric protein intolerance (LPI) is a rare autosomal recessive disorder affecting the basolateral transporter for cationic amino acids in the kidney and intestine leading to deficiency of these amino acids in blood (1, 2). Low levels of arginine and ornithine limit the functioning of the urea cycle resulting in high levels of ammonia accumulation affecting the brain and other organs.

A three year old child born following a consanguinuous relationship had presented to us with an eight month history of daily episodic irritability lasting for up to 12 hours. There was associated slow cognitive regression. The child was being treated for epilepsy with multiple anticonvulsants without benefit.

His EEG was normal and MRI had shown symmetrical periventricular T2 hyperintensities. On clinical examination he was pale, ataxic and had hepatosplenomegaly. His plasma ammonia was significantly raised at 840 micromol/L (normal range <35) as was plasma ferritin with mild derangement of liver function. Clinically Lysinuric proteinuric intolerance was suspected.

Plasma amino acids showed low levels of lysine, arginine and ornithine while urine organic acidogram showed elevated level of these aminoads . Urine organic acids was analyzed by GC-MS which demonstrated elevated levels of arctic acid (around 460 fold).

The child showed dramatic improvement in his symptomatology after starting ammonia scavenging therapy (Sodium benzoate and Citrulline) and mild protein restriction in diet. Ammonia levels had normalised.

The clinical and biochemical investigations are consistent with the diagnosis of LPI and gene studies subsequently confirmed a homozygous c.158C>T mutation in exon 1 of the gene for LPI.
MUTATION SPECTRUM OF GLUTARYL-COA DEHYDROGENASE DEFICIENCY IN SOUTH INDIAN POPULATION WITH GLUTARIC ACIDURIA TYPE I

Lokesh Lingappa1, Akella Radharama Devi1, Jayanthi Undamatla1, Satish S1. 1Department of Paediatric Neurolgy, Rainbow Hospital for Women and Children, road No 10, Banjara Hills, Hyderabad 500034, India; 2Department of Genetics & Metabolic Medicine, Rainbow Children’s Hospital Hyderabad, India; 3Sandor Proteomics Ltd Hyderabad, India

Glutaric Aciduria (GA I) is a commonly reported organic aciduria in India and the spectrum of mutations in the GCDH gene were not reported in the Indian population. Mutation analysis was done in twelve patients with biochemically confirmed cases of GA I. Glutaryl-CoA dehydrogenase (GCDH) gene was sequenced in these families and identified seven novel mutations in twelve families. The mutations were mostly missense. Homozygous mutations were seen in 9 families, one heterozygous mutation and a benign SNP in two families. No phenotype correlation could be made except in those families with a benign SNP and heterozygous mutation where the phenotype was milder and response to treatment was good. Genetic evaluation is useful in counselling families with regard to prenatal diagnosis and reproductive options. Mutation analysis is a useful tool in the absence of availability of enzyme assay for GA I in India.

CHRONIC PERIPHERAL NEUROPATHY PROGRESSING TO ENCEPHALOPATHY AS A RESULT OF LEAD INTOXICATION

Harshuti Biren Shah1, Hiren Trivedi2. 1Rajvee Child Neuro Hospital, India; 2Department of Paediatric Neurology, Rainbow Hospital for Women and Children, road No 10, Banjara Hills, Hyderabad 500034, India

Here we report 2 cases of younger children who had persistent anorexia. In the course of time, with persistent exposure they developed peripheral neuropathy. One of the children remained undiagnosed for 4 months and with peripheral neuropathy she progressed to the state of encephalopathy. In both cases the symptomatology was found to be due to lead intoxication. Both of them were treated using chelation therapy. Use of D penicillamine was sufficient for treatment of peripheral neuropathy. For lead encephalopathy we had to use Inj BAL and Inj Edetate calcium in combination. Chelation therapy had given satisfactory improvement in both cases. Herbal medicine (Ayurvedic) given for the long period of time was the source of Lead. We recommend lead intoxication to be thought of in patients presenting with chronic neuropathy and a rare cause of encephalopathy. However any medicine whether it is herbal or not to be used judiciously.

MULTIPLE CARBOXYLASE DEFICIENCY PRESENTING AS ACUTE ENCEPHALOPATHY

Harshuti Biren Shah1, Sumali Desai2. 1Rajvee Child Neuro Hospital, India; 2Infocus diagnostics, Ahmedabad, India

We present a case of 6 months old female child who was born of nonconsanguineous marriage. She had normal neurodevelopment till the age of 6 months. On administration of top feeding with high protein formula, she developed severe dystonia of both limbs. She had severe acidosis with moderately high lactate and ammonia. Her blood sugar was within normal range with normal range of all electrolytes. She was treated as metabolic acidosis with plenty of dextrose combined with insulin drip. MRI showed symmetrical lesions in global pallidi which showed elevated choline and lactate peak on MR spectroscopy. There were punctuate haemorrhages in right parietal region. Her tandem mass spectrometry showed very high CS OH and urine gas chromatography revealed metabolites of multiple carboxylase deficiency. Her biotinidase enzyme assay was 3 microgram/dl. She was given biotin 10 mg twice a day. Initially, she was conscious with relief of dystonia she developed fulminating fungal infection of intestine later on. However she died of fulminating fungal septicaemia. Multiple carboxylase is a rare autosomal recessive disorder which usually manifests in infancy. Good outcome with Biotin is well known but it could be fulminating in few. Our case reminds to institute compulsory new born screening for metabolic disorders in the developing countries like India.
**P264**

**X-LINKED ADRENOLEUKODYSTROPHY IN CHILDHOOD**
Kim Eun Young, Kwangu Christian Hospital, South Korea

**Purpose:** X-linked adrenoleukodystrophy (ALD) is a rare disorder that shows a great deal of phenotypic variability. We subdivided childhood X-linked ALD patients into several phenotypes by the age at onset, the sites of most severe clinical involvement and the rate of progression of neurologic symptoms.

**Methods:** Fourteen patients who had been diagnosed as X-linked ALD and followed up for at least one year were enrolled from 1996 to 2010.

**Results:** 1. eleven had childhood cerebral ALD, who showed first neurologic symptoms at 7.29 years and progressed rapidly; interval between first symptoms and vegetative state was 1.48 years, and interval from initial symptoms to death was 3.44 years. Treatment with Lorenzo’s oil did not prevent neurologic progression. Two patients who underwent umbilical cord blood transplantation died. 2. Two had adolescent cerebral ALD. They had first symptoms at 11.5 years, and showed tendency to progress less rapidly than childhood cerebral form patients. 3. One “Addison only” patient who had adrenal insufficiency without nervous system involvement remained asymptomatic during Lorenzo’s oil treatment. 4. Most cerebral form patients except two showed the lesions in both parieto-occipital white matter in brain magnetic resonance imaging.

**Conclusion:** The cerebral ALD was the most common form in childhood and was associated with a worse prognosis.

**P265**

**BIOTIN RESPONSIVE BASAL GANGLIA DISEASE : UNUSUAL PRESENTATION WITH SPINAL CORD INVOLVEMENT**
Fahad A. Bashiri, Muddathre HA Hamad, Heba Y. El khashabi, Saeed Hassan, Hamdy H. Hassan, Mustafa AM Salih. Division of Neurology,Department of Pediatrics, Faculty of Medicine & King Khalid University Hospital, King Saud University,Riyadh, Saudi Arabia

**Background:** Biotin responsive basal ganglia disease (BBGD) is a recessively inherited disorder manifested as subacute encephalopathy. It is a rare disorder related to thiamine transporter II deficiency caused by mutation in SLC19A3 gene. Administration of high dose of Biotin and thiamine resulted in significant improvement. Here we report 2 cases of BBGD with different clinical presentation and one with cervical spinal cord involvement.

**Case (1):** A 13-year-old girl who presented with a 5 days history of unsteady gait, her brother died at age of 2 years with similar presentation. Her clinical examination showed dystonia. Laboratory investigations showed normal amino acids and urine organic acids profile. MRI brain showed subcortical white matter lesions with high signal intensity involving the basal ganglia, cerebral and cerebellar white matter with alteration in signal intensity of cortical spine. She was diagnosed initially as Acute Disseminating Encephalomyelitis (ADEM), received IMG and methylprednisolone without much improvement. DNA test identifies mutation in SLC19A3 gene. Administration of high dose Biotin and thiamine reverses the symptoms.

**Case (2):** A 2-year-old girl who presented with a 5 days history of unsteady gait, her brother died at age of 2 years with similar presentation. Her clinical examination showed dystonia. Laboratory investigations showed normal amino acids and urine organic acids profile. MRI brain demonstrated high signal intensity in subcortical white matter, red nuclei and basal ganglia bilaterally. DNA confirmed the diagnosis of BBGD. She responded dramatically to high dose of Biotin and thiamine.

**Conclusion:** BBGD is a rare disorder that should be suspected in patients with subacute encephalopathy and acute dystonia as early recognition and treatment prevents serious complications and eventually death.

**P266**

**EPILEPSY AS A FORM OF PRESENTATION OF HYPERPROLINEMIA TYPE I : A PURPOSE OF TWO CASES**
Ana Isabel Maraña-Pérez, Teresa Escobar-Delgado, Immaculada Carreras-Sáez, Verónica Puertas-Martín, Jana Domínguez-Carral, Laura López-Marin. Hospital Infantil Universitario Niño Jesús, Madrid, Spain

**OBJECTIVES:** Hyperprolinemia type I (HPI) is an inborn error of metabolism caused by proline gene alteration proline dehydrogenase (PRODH) on chromosome 22q11, which causes increased levels of proline in plasma and urine by decreasing the activity of the proline oxidase (POX). Clinical manifestations can find cognitive and psychiatric disorders, epilepsy and kidney impairment. We present two cases with different clinical expression of HPI.

**CLINICAL OBSERVATIONS:** The first case is a girl who presented development delay and hypotonia at birth and whose Exploration showed macrocephaly, prominent forehead, flattened nasal nose and hypertelorism. Family and personal history normal. With three years starts episodes of cessation of motor activity without automation or abnormal movements of seconds long. EEGs are displayed in several abnormalities multifocal. Shows increase in metabolic study of plasma proline and proline and hydroxyproline increased urine HPI diagnostic support.

The second case is a child with normal physical examination, personal history and family without interest starts at 2 years and 4 months simple partial seizures refractory to antiepileptic treatment. Several electroencephalograms show a right frontotemporal focus. On several occasions the patient had episodes of ataxia associated with fever and intake of certain drugs (phenytoin and oxcarbazepine). In which an increased metabolic study of plasma and urine proline, hydroxyproline and glycine increased in urine and increased glutamine cerebrospinal fluid compatible with all HPI.

**COMMENTS:** HPI can present with various clinical manifestations, among which predominate seizure. This entity should be included in the differential diagnosis of a child with epilepsy, especially if refractory.

**P267**

**LIFE EXPECTANCY OF LEIGH SYNDROME IN INFANTS AND CHILDREN**
Ching-Shang Chi., ‘Department of Pediatrics, Tung’s Taichung Metro Hospital, Taiwan

**Introduction:** Leigh syndrome, caused by dysfunction in mitochondrial energy metabolism, is an inherited, heterogeneous and progressive neurodegenerative disorder in infancy and childhood. The aim of this study is to analyze the life expectancy in patients with Leigh syndrome from clinical and genetic features.

**Methods:** From 1983 to March 2012, 30 patients diagnosed with Leigh syndrome by characteristic neuromaging findings, abnormal biochemical staining and/or abnormal mitochondrial configurations of the muscle cells, and/or pathognomonic mitochondrial gene mutations.

**Results:** 22 of 30 cases presented clinical features before age of one year. All of them presented with variable symptoms of CNS involvement. The first three common symptoms were developmental delay, seizures, and altered level of consciousness. Extra-CNS manifestations were not uncommon, including pericardial effusion, cardiac rhythm disorder, ophthalmologic disorders, hypotonia, and abnormal movements of seconds long. EEGs are displayed in several abnormalities multiform. Shows increase in metabolic study of plasma and urine proline, hydroxyproline and glycine increased in urine and increased glutamine cerebrospinal fluid compatible with all HPI.

**COMMENTS:** HPI can present with various clinical manifestations, among which predominate seizure. This entity should be included in the differential diagnosis of a child with epilepsy, especially if refractory.

**P268**

**CHARACTERIZATION OF BEHAVIORAL AND SEIZURE RELATED MANIFESTATIONS OF GUANIDINOACETATE-METHYLTRANSFERASE DEFICIENCY.**
Gulcin Akinci1, Unsal Yilmaz1, Orkide Guzel 1, Gajja S Salomons 2. 1Dr. Behçet Uz Children’s Hospital, Izmir, Turkey; 2VU Medical Center, Amsterdam, Netherlands

Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive error of creatine synthesis characterized by cerebral creatine deficiency, accumulation of guanidinoacetate, mental retardation, epilepsy and extrapyramidal signs. Patients with GAMT deficiency have an unspecific but relatively constant clinical presentation.

We presented the behavioural and seizure related manifestations of two siblings with GAMT deficiency and compared their clinical phenotype to the related literature. Our patients, an 8-year and 14-year
old boys with GAMT deficiency, presented mental retardation, epilepsy and autistic behaviour. Diagnosis was done by brain magnetic resonance spectroscopy, biochemical and genetic procedures (guanidinoacetate quantification, determination of GAMT activity and mutation analysis in the GAMT gene). GAMT gene was analyzed by DNA sequence analysis: the homozygous c.326A>G mutation was detected. This mutation is predicted to result in a missense mutation (one amino acid replacement) or in erroneous splicing. The mutation was not detected before in any other patient with GAMT deficiency or in 13000 other controls. GAMT deficiency is treatable; therefore, its early diagnosis might be critical, to prevent irreversible brain damage. It must be considered in the differential diagnosis of the broad range of unexplained neuropsychiatric disorders with epilepsy in children and it can be ruled out/detected by using brain magnetic resonance spectroscopy and/or by guanidinoacetate and creatine measurements in body fluids.

P269
INFANTILE NEURONAL CEROID LIPOFUSCINOSIS “CASE REPORT”
Cihan Meral. GATA Haydarpasa Teaching Hospital, Pediatry Department , Uskudar, Istanbul, Turkey
Neuronal ceroid lipofuscinoses (NCLs; also known collectively as Batten Disease) are a family of autosomal recessive lysosomal storage disorders. Mutations in as many as 13 genes give rise to ~10 variants of Batten Disease. All overlap clinical symptomatology including visual impairment, motor and cognitive dysfunction, seizures, and premature death.
Case Description: A four-year-old boy, referred to our service with seizures and progressive neuromotor retardation. The patients and his family’s history are not specific. The patients mental and motor development are normal until 18 months. After the 18th months the motor retardations begun with walking disorder. Following this, the patient had febrile and afebrile seizures. In physical examination the general condition moderate, the response to pain is just groaning. Bilateral light and corneal reflexes are absent. He is microcephalic (<3th percentile), The deep tendon reflexes in the lower extremities are more alert. He couldn’t sit with support and also couldn’t speak too. The laboratory tests including hemogram, serum biochemistry, metabolic screening were all normal. In cranial magnetic resonans imaging (MRI) there was cortical atrophy and volume deficit in the gyrus seen. In electroencephalogram (EEG) in both temporoparietal occipital region, asencronized sharp wave forms were seen. After these finding further evaluation done and in genetic analyse, (1p32 ) c.539C>T (p.H187Y) homozygote mutation shown in the palmitoil protin tyoesterase 1 (PPT1) gene. This mutation has not been shown in another case in literature.

P270
HALLERVORDEN-SPATZ CASE REPORT “CASE REPORT”
Selami Suleymangolu, 1 Cihan MERAL, 1 GATA Haydarpasa Teaching Hospital, Pediatry Department , Uskudar/ISTANBUL
Hallervorden-Spatz disease is a neurodegenerative disorder associated with cysteine-iron complex accumulation typically seen as bilateral symmetrical hypointense signal changes in the medial globus pallidus on magnetic resonance imaging. Both familial and sporadic cases have been reported.
A 5-year-old boy presented with a 2 year history of abnormal flexor posturing of the right hand and wrist with clenching of the fist, abnormal speech, attention deficit and ataxic walking. His developmental milestones were delayed and speech was slurred with inability to speak difficult words. Over 6 months it became fixed and persistent and also involved the left hand. Subsequently, he developed extension of the neck and flexion of the trunk, with grimacing of the face, tight closure of the mouth and deterioration of speech and walking. He was the product of a non-consanguineous marriage and was born at 34 weeks gestation. MRI showed hypointensity on T1 weighted imaging in both globus pallidii and an area of central hyperintensity (“eye-of-the-tiger”-sign) in both globus pallidi on T2 weighted imaging. After the MRI findings, the cytogenetic analyse done and, it showed, c.628+2T>G (homozygote). This mutation hasn’t been defined before, so it should be valuable in diagnosing Hallervorden-Spatz patients.

P271
AN INFREQUENT NEURORADIOLOGICAL FINDING IN MENKES DISEASE
Mohamed Osman Eltahir Babiker, Mary O’Regan. Fraser of Allander Neurosciences Unit, Royal Hospital for Sick Children, Glasgow, United Kingdom
BACKGROUND: Menkes disease is a relatively rare X-linked neurodegenerative disorder of copper transport secondary to mutations in the ATP7A gene. Grey and white matter abnormalities and spontaneous intracranial bleeding are well documented radiological findings. However, lactate peak on magnetic resonance spectroscopy (MRS) is less frequently described. This is commonly observed in a range of metabolic disorders typically mitochondrial diseases. When reported in Menkes disease, it is thought to result from energy failure due to deficiency of copper-containing enzymes.
AIM: To describe an infrequent finding on MRS in an unusual case of Menkes disease. CASE REPORT: This 29-week preterm boy presented at the corrected age of two months with episodes of hypothermia, lethargy and poor feeding. He had a difficult early neonatal course complicated by episodes of sepsis and hypothermia. During this presentation, he had episodes of tonic posturing and unresponsiveness that subsequently led to mechanical ventilation. Maintaining his body temperature within normal limits was difficult. Interestingly, he had very little body hair. A brain MRI scan demonstrated bifrontal chronic subdural haemorrhages, white matter loss and delayed myelination. MRS revealed a positive lactate peak in both basal ganglia and white matter. Both plasma and CSF lactate levels were normal. Plasma copper and caeruloplasmin were markedly low. A missense mutation in the ATP7A gene was found.
DISCUSSION & CONCLUSION: The differential diagnosis of a lactate peak on MRS in a male infant presenting with unusual neurologic manifestations should be expanded to include Menkes disease.

P272
LEUKOENCEPHALOPATHY IS A COMMON FINDING IN CHILDHOOD ONSET MITOCHONDRIAL DISEASE?
Srividi Sreekantam, Anupam Chakrapsani, Katharine Foster, Lesley Macpherson, Louise Simmons, Saikat Santra, Suresh Vijay, Evangeline Wasmir. Birmingham Children’s Hospital, Country, United Kingdom
Neuroimaging plays a vital role in the diagnosis of mitochondrial neurodegenerative disease. Grey matter abnormalities and stroke-like lesions are considered to be signature findings. We report the findings of children with white matter involvement or leukoencephalopathy in a cohort of children with suspected mitochondrial neurological disease.
AIM: To establish the frequency of white matter changes on neuroimaging in a cohort of children with suspected mitochondrial disease.
Method: Retrospective review of children with suspected mitochondrial neurological disorder over a 6 year period (April 2007 to 2013). We collected clinical, neuroimaging, biochemical and molecular genetic data.
Results: In the cohort of 108 children with suspected mitochondrial neurological disease, 54 (50%) had multisystem involvement, ophthalmoplegia and cardiac involvement are common comorbidities. 47 (43.5%) had predominantly white matter disease on neuroimaging, consisting of high T2 signal of deep cerebral and periventricular white matter. 30/47 (63%) had isolated white matter changes, 12/47 (25%) had white matter and basal ganglia changes and 5/47 (10%) had atrophy and abnormal white matter.
In the mitochondrial leukoencephalopathy group, a molecular genetic diagnosis was obtained in 40%, 19/47 (17 nuclear, 2 mitochondrial DNA mutations). In the 28 children without a molecular genetic diagnosis, 17/28 (60%) had abnormal respiratory chain in muscle, 2/28 abnormal muscle histology, 6/9 raised CSF lactate and 7/25 raised plasma lactate.
Conclusion: In our cohort of suspected mitochondrial disorders, leukoencephalopathy is common. The finding of leukoencephalopathy in a child with neurological and multisystem involvement should prompt a thorough evaluation for mitochondrial disease.
P273
EFFECT OF MIGLUSTAT ON NEUROLOGICAL OUTCOME IN EARLY INFANTILE NIEMANN PICK C
Sivridya Streekarn, Evangeline Wassmer, Suresh Vijay, Sakat Santra, Louise Simmons, Anupam Chakrapani. Birmingham Children’s Hospital, Birmingham B4 6NH

Miglustat, a small iminosugar with its ability to cross the blood brain barrier has proved disease-modifying benefit on neurological manifestations in Niemann Pick type C1 (NPC1). We report the benefit of early use of this drug in infantile onset NPC1.

Case report: A female infant presented with neonatal cholestasis and hepatosplenomegaly and was diagnosed with NPC1. Her previous affected male sibling had early onset NPC1 with similar presentation. She was in a vegetative state by 4 years and died aged six.

She was started on Miglustat at 5 months of age after cholestasis resolved. At 30 months of age, her Niemann Pick disease related disability score was 4 with normal ambulation, manipulation, language and swallowing.

Development assessment at 3 years of age using Bailey scales showed a cognitive age of 19 months and gross motor age of 1 year. At 4 years of age she is able to run and climb onto furniture, she remains neurologically stable and continues to make developmental progress with no signs of regression.

Discussion: Early treatment with Miglustat significantly altered the disease course in this patient compared with the sibling, highlighting the importance of early diagnosis of neurological disease in NPC1.

P274
ASSOCIATION OF DERMAL MELANOCYTOSIS WITH GM1-GANGLIOSIDOSIS TYPE 1
Lucia Cibils1, Francisco Espinel1, Conrado Medici1, Marela Alvarez2, Natalia Donado2, Andrea Rey2, Ada Lemes1, Gabriel Gonzalez1. 1Pediatric Neurology Department - Pereira Rossell Children’s Hospital, Montevideo, Uruguay; 2Dermatology Department - Pereira Rossell Children’s Hospital, Montevideo, Uruguay

Introduction: Lysosomal storage disorders (LSD) are characterized by the accumulation of partially degraded insoluble metabolites within lysosomes. GM1-gangliosidosis type 1 is a hereditary deficiency of lysosomal acid beta-galactosidase, particularly severe entity with marked central nervous system involvement. Facial dysmorphism, hepatosplenomegaly, and generalized skeletal dysplasia are usually present in infantile cases. Dermal melanocytosis encompasses a clinical spectrum of cutaneous diseases such as Mongolian spots among others. The association of dermal melanocytosis with LSD is uncommon and still poorly understood. We report here a case of dermal melanocytosis associated with GM1-gangliosidosis type 1.

Patient: A 9-month-old Caucasian boy referred for evaluation of severe generalized hypotonia, lethargy and developmental delay. Extensive and unusual blue macules resembling Mongolian spots with larger lesions distributed over posterior trunk and axilla were found. In addition to the skin lesions, the infant had coarse facial features with low nasal bridge, broad nose, long philtrum; gingival hypertrophy, hepatomegaly, bilateral hydrocele and lumbar kyphosis also were found. Blood count reveal vacuolated lymphocytes. Elevated urine oligosaccharides and beta galactosidase activity deficient confirm the diagnosis of GM1.

Discussion: In the appropriate clinical setting, an unusual presentation of dermal melanocytosis may be a cutaneous sign of an underlying LSD.